RNS Number:2542U
Protherics PLC
15 January 2004


Thursday 15th January, 2004

Protherics PLC announcement

Protherics PLC ("Protherics"), the international biopharmaceuticals company,
acknowledges the recent announcement by Abbott Laboratories of a veterinary
biological product license application to market and distribute Enfer Scientific
Limited's bovine spongiform encephalopathy (BSE) test in the US. This follows a
call for applications issued by the US Department of Agriculture last week
following the recent case of BSE in cattle in the US.

Protherics has licensed to Enfer its intellectual property in the diagnosis of
animal prion diseases, including BSE. Enfer has developed a rapid post-mortem
BSE test for cattle testing which has been approved for use in the EU. Enfer
markets the BSE test in Ireland and has sublicensed the technology to Abbott for
distribution on a worldwide basis. Protherics receives royalties from Enfer on
sales of the test worldwide. Protherics understands that currently there are no
rapid BSE tests commercially available in the US.


                                      ENDS

For further information contact:

Protherics PLC - Tel +44 (0) 20 7246 9950
Andrew Heath, Chief Executive - Tel +44 (0) 7919 480510 (mobile)

The Maitland Consultancy +44 (0) 20 7379 5151
Brian Hudspith/ Michelle Jeffery


Protherics PLC

Protherics PLC was formed in September 1999 from the merger of Proteus
International plc and Therapeutic Antibodies Inc. Protherics is an international
biopharmaceutical company, engaged in the development, production and
commercialisation of immunopharmaceuticals and cancer therapies.

The Company's ordinary shares are listed on the Official List of the UK Listing
Authority and are traded on the London Stock Exchange. (PTI.L)

An electronic version of this will be available at: www.protherics.com

This release, and oral statements made from time to time by Company
representatives concerning the subject matter hereof, may contain so-called
"forward looking statements". These statements can be identified by introductory
words such as "expects", "plans", "will", "estimates", "forecasts", "projects",
words of similar meaning, and by the fact that they do not relate strictly to
historical or current facts. Forward-looking statements frequently are
discussing the Company's growth strategy, operating and financial goals, plans
relating to regulatory submissions and approvals and development programs. Many
factors may cause actual results to differ from the Company's forward-looking
statements, including inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not. Those and
other risks are described in the Company's filings with the Securities and
Exchange Commission, copies of which are available from the SEC or may be
obtained upon request from the Company. No forward-looking statement is a
guarantee of future results or events, and one should avoid placing undue
reliance on such statements.






                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCUSOBRSVRAAAR